OTC Pharmaceuticals Global Group of Eight (G8) Industry Guide_2016

Date: October 19, 2016
Pages: 185
Price:
US$ 1,495.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O33C2F73BBAEN
Leaflet:

Download PDF Leaflet

SUMMARY

The G8 OTC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY FINDINGS
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the G8 otc pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 otc pharmaceuticals market
  • Leading company profiles reveal details of key otc pharmaceuticals market players' G8 operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the G8 otc pharmaceuticals market with five year forecasts by both value and volume
  • Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
SYNOPSIS

Essential resource for top-line data and analysis covering the G8 otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

REASONS TO BUY
  • What was the size of the G8 otc pharmaceuticals market by value in 2015?
  • What will be the size of the G8 otc pharmaceuticals market in 2020?
  • What factors are affecting the strength of competition in the G8 otc pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the G8 otc pharmaceuticals market?
KEY HIGHLIGHTS
  • These Countries contributed $72,703.0 million in 2015 to the global otc pharmaceuticals industry, with a compound annual growth rate (CAGR) of 2.2% between 2011 and 2015. The G8 countries are expected to reach a value of $80,376.4 million in 2020, with a CAGR of 2% over the 2015-20 period.
  • Among the G8 nations, the US is the leading country in the otc pharmaceuticals industry, with market revenues of $38,718.7 million in 2015. This was followed by Japan and Germany, with a value of $10,136.7 and $6,256.7 million, respectively.
  • The US is expected to lead the otc pharmaceuticals industry in the G8 nations with a value of $43,383.7 million in 2016, followed by Japan and Germany with expected values of $10,741.5 and $6,405.6 million, respectively.
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Group of Eight (G) OTC Pharmaceuticals
Industry Outlook
OTC Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

LIST OF TABLES

Table 1: G8 otc pharmaceuticals industry, revenue($m), 2011-20
Table 2: G8 otc pharmaceuticals industry, revenue by country ($m), 2011-15
Table 3: G8 otc pharmaceuticals industry forecast, revenue by country ($m), 2015-20
Table 4: Canada OTC pharmaceuticals market value: $ million, 2011-15
Table 5: Canada OTC pharmaceuticals market category segmentation: $ million, 2015
Table 6: Canada OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 7: Canada OTC pharmaceuticals market share: % share, by value, 2015
Table 8: Canada OTC pharmaceuticals market distribution: % share, by value, 2015
Table 9: Canada OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 10: Canada size of population (million), 2011-15
Table 11: Canada gdp (constant 2005 prices, $ billion), 2011-15
Table 12: Canada gdp (current prices, $ billion), 2011-15
Table 13: Canada inflation, 2011-15
Table 14: Canada consumer price index (absolute), 2011-15
Table 15: Canada exchange rate, 2011-15
Table 16: France OTC pharmaceuticals market value: $ million, 2011-15
Table 17: France OTC pharmaceuticals market category segmentation: $ million, 2015
Table 18: France OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 19: France OTC pharmaceuticals market share: % share, by value, 2015
Table 20: France OTC pharmaceuticals market distribution: % share, by value, 2015
Table 21: France OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 22: France size of population (million), 2011-15
Table 23: France gdp (constant 2005 prices, $ billion), 2011-15
Table 24: France gdp (current prices, $ billion), 2011-15
Table 25: France inflation, 2011-15
Table 26: France consumer price index (absolute), 2011-15
Table 27: France exchange rate, 2011-15
Table 28: Germany OTC pharmaceuticals market value: $ million, 2011-15
Table 29: Germany OTC pharmaceuticals market category segmentation: $ million, 2015
Table 30: Germany OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 31: Germany OTC pharmaceuticals market share: % share, by value, 2015
Table 32: Germany OTC pharmaceuticals market distribution: % share, by value, 2015
Table 33: Germany OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 34: Germany size of population (million), 2011-15
Table 35: Germany gdp (constant 2005 prices, $ billion), 2011-15
Table 36: Germany gdp (current prices, $ billion), 2011-15
Table 37: Germany inflation, 2011-15
Table 38: Germany consumer price index (absolute), 2011-15
Table 39: Germany exchange rate, 2011-15
Table 40: Italy OTC pharmaceuticals market value: $ million, 2011-15
Table 41: Italy OTC pharmaceuticals market category segmentation: $ million, 2015
Table 42: Italy OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 43: Italy OTC pharmaceuticals market share: % share, by value, 2015
Table 44: Italy OTC pharmaceuticals market distribution: % share, by value, 2015
Table 45: Italy OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 46: Italy size of population (million), 2011-15
Table 47: Italy gdp (constant 2005 prices, $ billion), 2011-15
Table 48: Italy gdp (current prices, $ billion), 2011-15
Table 49: Italy inflation, 2011-15
Table 50: Italy consumer price index (absolute), 2011-15
Table 51: Italy exchange rate, 2011-15
Table 52: Japan OTC pharmaceuticals market value: $ million, 2011-15
Table 53: Japan OTC pharmaceuticals market category segmentation: $ million, 2015
Table 54: Japan OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 55: Japan OTC pharmaceuticals market share: % share, by value, 2015
Table 56: Japan OTC pharmaceuticals market distribution: % share, by value, 2015
Table 57: Japan OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 58: Japan size of population (million), 2011-15
Table 59: Japan gdp (constant 2005 prices, $ billion), 2011-15
Table 60: Japan gdp (current prices, $ billion), 2011-15
Table 61: Japan inflation, 2011-15
Table 62: Japan consumer price index (absolute), 2011-15
Table 63: Japan exchange rate, 2011-15
Table 64: Russia OTC pharmaceuticals market value: $ million, 2011-15
Table 65: Russia OTC pharmaceuticals market category segmentation: $ million, 2015
Table 66: Russia OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 67: Russia OTC pharmaceuticals market share: % share, by value, 2015
Table 68: Russia OTC pharmaceuticals market distribution: % share, by value, 2015
Table 69: Russia OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 70: Russia size of population (million), 2011-15
Table 71: Russia gdp (constant 2005 prices, $ billion), 2011-15
Table 72: Russia gdp (current prices, $ billion), 2011-15
Table 73: Russia inflation, 2011-15
Table 74: Russia consumer price index (absolute), 2011-15
Table 75: Russia exchange rate, 2011-15
Table 76: United Kingdom OTC pharmaceuticals market value: $ million, 2011-15
Table 77: United Kingdom OTC pharmaceuticals market category segmentation: $ million, 2015
Table 78: United Kingdom OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 79: United Kingdom OTC pharmaceuticals market share: % share, by value, 2015
Table 80: United Kingdom OTC pharmaceuticals market distribution: % share, by value, 2015
Table 81: United Kingdom OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 82: United Kingdom size of population (million), 2011-15
Table 83: United Kingdom gdp (constant 2005 prices, $ billion), 2011-15
Table 84: United Kingdom gdp (current prices, $ billion), 2011-15
Table 85: United Kingdom inflation, 2011-15
Table 86: United Kingdom consumer price index (absolute), 2011-15
Table 87: United Kingdom exchange rate, 2011-15
Table 88: United States OTC pharmaceuticals market value: $ million, 2011-15
Table 89: United States OTC pharmaceuticals market category segmentation: $ million, 2015
Table 90: United States OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 91: United States OTC pharmaceuticals market share: % share, by value, 2015
Table 92: United States OTC pharmaceuticals market distribution: % share, by value, 2015
Table 93: United States OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 94: United States size of population (million), 2011-15
Table 95: United States gdp (constant 2005 prices, $ billion), 2011-15
Table 96: United States gdp (current prices, $ billion), 2011-15
Table 97: United States inflation, 2011-15
Table 98: United States consumer price index (absolute), 2011-15
Table 99: United States exchange rate, 2011-15
Table 100: GlaxoSmithKline Plc: key facts
Table 101: GlaxoSmithKline Plc: key financials ($)
Table 102: GlaxoSmithKline Plc: key financials (£)
Table 103: GlaxoSmithKline Plc: key financial ratios
Table 104: Johnson and Johnson: key facts
Table 105: Johnson and Johnson: key financials ($)
Table 106: Johnson and Johnson: key financial ratios
Table 107: Pfizer Inc.: key facts
Table 108: Pfizer Inc.: key financials ($)
Table 109: Pfizer Inc.: key financial ratios
Table 110: Sanofi SA: key facts
Table 111: Sanofi SA: key financials ($)
Table 112: Sanofi SA: key financials (€)
Table 113: Sanofi SA: key financial ratios
Table 114: The Procter and Gamble Company: key facts
Table 115: The Procter and Gamble Company: key financials ($)
Table 116: The Procter and Gamble Company: key financial ratios
Table 117: Reckitt Benckiser Group plc: key facts
Table 118: Reckitt Benckiser Group plc: key financials ($)
Table 119: Reckitt Benckiser Group plc: key financials (£)
Table 120: Reckitt Benckiser Group plc: key financial ratios
Table 121: Almirall S.A.: key facts
Table 122: Almirall S.A.: key financials ($)
Table 123: Almirall S.A.: key financials (€)
Table 124: Almirall S.A.: key financial ratios
Table 125: Boehringer Ingelheim GmbH: key facts
Table 126: Boehringer Ingelheim GmbH: key financials ($)
Table 127: Boehringer Ingelheim GmbH: key financials (€)
Table 128: Boehringer Ingelheim GmbH: key financial ratios
Table 129: Novartis AG: key facts
Table 130: Novartis AG: key financials ($)
Table 131: Novartis AG: key financial ratios
Table 132: Daiichi Sankyo Co., Ltd.: key facts
Table 133: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 134: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 135: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 136: Kracie Holdings, Ltd.: key facts
Table 137: JSC ELFA: key facts
Table 138: The Menarini Group: key facts
Table 139: The Menarini Group: key financials ($)
Table 140: The Menarini Group: key financials (€)
Table 141: The Menarini Group: key financial ratios
Table 142: Pharmstandard OJSC: key facts
Table 143: Pharmstandard OJSC: key financials ($)
Table 144: Pharmstandard OJSC: key financials (RUB)
Table 145: Pharmstandard OJSC: key financial ratios
Table 146: Bayer AG: key facts
Table 147: Bayer AG: key financials ($)
Table 148: Bayer AG: key financials (€)
Table 149: Bayer AG: key financial ratios

LIST OF FIGURES

Figure 1: G8 otc pharmaceuticals industry, revenue($m), 2011-20
Figure 2: G8 OTC Pharmaceuticals industry, revenue by country (%), 2015
Figure 3: G8 otc pharmaceuticals industry, revenue by country ($m), 2011-15
Figure 4: G8 otc pharmaceuticals industry forecast, revenue by country ($m), 2015-20
Figure 5: Canada OTC pharmaceuticals market value: $ million, 2011-15
Figure 6: Canada OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 7: Canada OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 8: Canada OTC pharmaceuticals market share: % share, by value, 2015
Figure 9: Canada OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 10: Canada OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 11: Forces driving competition in the OTC pharmaceuticals market in Canada, 2015
Figure 12: Drivers of buyer power in the OTC pharmaceuticals market in Canada, 2015
Figure 13: Drivers of supplier power in the OTC pharmaceuticals market in Canada, 2015
Figure 14: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Canada, 2015
Figure 15: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Canada, 2015
Figure 16: Drivers of degree of rivalry in the OTC pharmaceuticals market in Canada, 2015
Figure 17: France OTC pharmaceuticals market value: $ million, 2011-15
Figure 18: France OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 19: France OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 20: France OTC pharmaceuticals market share: % share, by value, 2015
Figure 21: France OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 22: France OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 23: Forces driving competition in the OTC pharmaceuticals market in France, 2015
Figure 24: Drivers of buyer power in the OTC pharmaceuticals market in France, 2015
Figure 25: Drivers of supplier power in the OTC pharmaceuticals market in France, 2015
Figure 26: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in France, 2015
Figure 27: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in France, 2015
Figure 28: Drivers of degree of rivalry in the OTC pharmaceuticals market in France, 2015
Figure 29: Germany OTC pharmaceuticals market value: $ million, 2011-15
Figure 30: Germany OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 31: Germany OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 32: Germany OTC pharmaceuticals market share: % share, by value, 2015
Figure 33: Germany OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 34: Germany OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 35: Forces driving competition in the OTC pharmaceuticals market in Germany, 2015
Figure 36: Drivers of buyer power in the OTC pharmaceuticals market in Germany, 2015
Figure 37: Drivers of supplier power in the OTC pharmaceuticals market in Germany, 2015
Figure 38: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Germany, 2015
Figure 39: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Germany, 2015
Figure 40: Drivers of degree of rivalry in the OTC pharmaceuticals market in Germany, 2015
Figure 41: Italy OTC pharmaceuticals market value: $ million, 2011-15
Figure 42: Italy OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 43: Italy OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 44: Italy OTC pharmaceuticals market share: % share, by value, 2015
Figure 45: Italy OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 46: Italy OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 47: Forces driving competition in the OTC pharmaceuticals market in Italy, 2015
Figure 48: Drivers of buyer power in the OTC pharmaceuticals market in Italy, 2015
Figure 49: Drivers of supplier power in the OTC pharmaceuticals market in Italy, 2015
Figure 50: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Italy, 2015
Figure 51: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Italy, 2015
Figure 52: Drivers of degree of rivalry in the OTC pharmaceuticals market in Italy, 2015
Figure 53: Japan OTC pharmaceuticals market value: $ million, 2011-15
Figure 54: Japan OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 55: Japan OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 56: Japan OTC pharmaceuticals market share: % share, by value, 2015
Figure 57: Japan OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 58: Japan OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 59: Forces driving competition in the OTC pharmaceuticals market in Japan, 2015
Figure 60: Drivers of buyer power in the OTC pharmaceuticals market in Japan, 2015
Figure 61: Drivers of supplier power in the OTC pharmaceuticals market in Japan, 2015
Figure 62: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Japan, 2015
Figure 63: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Japan, 2015
Figure 64: Drivers of degree of rivalry in the OTC pharmaceuticals market in Japan, 2015
Figure 65: Russia OTC pharmaceuticals market value: $ million, 2011-15
Figure 66: Russia OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 67: Russia OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 68: Russia OTC pharmaceuticals market share: % share, by value, 2015
Figure 69: Russia OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 70: Russia OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 71: Forces driving competition in the OTC pharmaceuticals market in Russia, 2015
Figure 72: Drivers of buyer power in the OTC pharmaceuticals market in Russia, 2015
Figure 73: Drivers of supplier power in the OTC pharmaceuticals market in Russia, 2015
Figure 74: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Russia, 2015
Figure 75: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Russia, 2015
Figure 76: Drivers of degree of rivalry in the OTC pharmaceuticals market in Russia, 2015
Figure 77: United Kingdom OTC pharmaceuticals market value: $ million, 2011-15
Figure 78: United Kingdom OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 79: United Kingdom OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 80: United Kingdom OTC pharmaceuticals market share: % share, by value, 2015
Figure 81: United Kingdom OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 82: United Kingdom OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 83: Forces driving competition in the OTC pharmaceuticals market in the United Kingdom, 2015
Figure 84: Drivers of buyer power in the OTC pharmaceuticals market in the United Kingdom, 2015
Figure 85: Drivers of supplier power in the OTC pharmaceuticals market in the United Kingdom, 2015
Figure 86: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in the United Kingdom, 2015
Figure 87: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in the United Kingdom, 2015
Figure 88: Drivers of degree of rivalry in the OTC pharmaceuticals market in the United Kingdom, 2015
Figure 89: United States OTC pharmaceuticals market value: $ million, 2011-15
Figure 90: United States OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 91: United States OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 92: United States OTC pharmaceuticals market share: % share, by value, 2015
Figure 93: United States OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 94: United States OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 95: Forces driving competition in the OTC pharmaceuticals market in the United States, 2015
Figure 96: Drivers of buyer power in the OTC pharmaceuticals market in the United States, 2015
Figure 97: Drivers of supplier power in the OTC pharmaceuticals market in the United States, 2015
Figure 98: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in the United States, 2015
Figure 99: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in the United States, 2015
Figure 100: Drivers of degree of rivalry in the OTC pharmaceuticals market in the United States, 2015
Figure 101: GlaxoSmithKline Plc: revenues & profitability
Figure 102: GlaxoSmithKline Plc: assets & liabilities
Figure 103: Johnson & Johnson: revenues & profitability
Figure 104: Johnson & Johnson: assets & liabilities
Figure 105: Pfizer Inc.: revenues & profitability
Figure 106: Pfizer Inc.: assets & liabilities
Figure 107: Sanofi SA: revenues & profitability
Figure 108: Sanofi SA: assets & liabilities
Figure 109: The Procter & Gamble Company: revenues & profitability
Figure 110: The Procter & Gamble Company: assets & liabilities
Figure 111: Reckitt Benckiser Group plc: revenues & profitability
Figure 112: Reckitt Benckiser Group plc: assets & liabilities
Figure 113: Almirall S.A.: revenues & profitability
Figure 114: Almirall S.A.: assets & liabilities
Figure 115: Boehringer Ingelheim GmbH: revenues & profitability
Figure 116: Boehringer Ingelheim GmbH: assets & liabilities
Figure 117: Novartis AG: revenues & profitability
Figure 118: Novartis AG: assets & liabilities
Figure 119: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 120: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 121: Pharmstandard OJSC: revenues & profitability
Figure 122: Pharmstandard OJSC: assets & liabilities
Figure 123: Bayer AG: revenues & profitability
Figure 124: Bayer AG: assets & liabilities
Skip to top


Ask Your Question

OTC Pharmaceuticals Global Group of Eight (G8) Industry Guide_2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: